Physicians Warn: 7-OH Patients Need Higher Buprenorphine Doses and Face Greater Treatment Complexity Than Kratom Users

Why it matters

Frontline clinicians are encountering 7-OH patients who require higher buprenorphine doses than typical kratom users, spend up to $1,500 per month on the substance, and face a more severe withdrawal profile — a practical warning the medical community needs to hear.

The big picture

7-OH products, sold openly at gas stations and smoke shops as "natural remedies," contain concentrations far exceeding those found in kratom leaf. The FDA formally requested DEA scheduling of 7-OH in mid-2025, but federal action remains pending while states scramble to legislate on their own. Clinicians report being largely unprepared to treat 7-OH dependence.

Key findings

• 7-OH is approximately 4–7 times more potent than morphine for pain relief in mouse models
• Patients transitioning off 7-OH require higher buprenorphine doses than those stopping natural kratom
• Some patients spend up to $1,500 per month on 7-OH products to prevent withdrawal
• 7-OH use is frequently unrecognized in clinical settings or conflated with natural kratom use
• Authors call for expanded access to low-dose, flexible buprenorphine induction protocols for 7-OH patients

What they say

"A coordinated public-health response is urgently needed to address the emerging risks of high-potency kratom-derived products such as 7-OH," wrote Drs. Emma Fenske and Bradley M. Buchheit.

Bottom line

**For clinicians: 7-OH is not just kratom — it is a distinct high-potency opioid that often demands more aggressive treatment and higher medication doses than conventional kratom use disorder.**